GSK-2239633, also known by its CAS number 2181665-31-4, is a chemical compound that has been investigated primarily in the context of pharmaceutical research. It is classified as a small molecule and is known to act as a selective inhibitor of certain biological pathways, particularly those involving kinases. The compound has shown potential in preclinical studies for its efficacy in treating various diseases, including certain types of cancer and autoimmune disorders. Its molecular structure typically features functional groups that enhance its binding affinity to target proteins, contributing to its biological activity. The compound's solubility, stability, and pharmacokinetic properties are critical for its development as a therapeutic agent. As with many investigational drugs, ongoing research is essential to fully understand its mechanism of action, safety profile, and potential therapeutic applications. However, specific details regarding its synthesis, detailed mechanism, and clinical trial outcomes may vary and should be referenced from current scientific literature for the most accurate and up-to-date information.

GSK2239633 is  a potent CC-chemokine receptor 4 antagonist with pIC50 of 7.9.  The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.

GSK-2239633

(GSK2239633)

2181665-31-4: GSK-2239633, also known by its CAS number 2181665-31-4, is a chemical compound that has been investigated primarily in the context of pharmaceutical research. It is classified as a small molecule and is known to act as a selective inhibitor of certain biological pathways, particularly those involving kinases. The compound has shown potential in preclinical studies for its efficacy in treating various diseases, including certain types of cancer and autoimmune disorders. Its molecular structure typically features functional groups that enhance its binding affinity to target proteins, contributing to its biological activity. The compound's solubility, stability, and pharmacokinetic properties are critical for its development as a therapeutic agent. As with many investigational drugs, ongoing research is essential to fully understand its mechanism of action, safety profile, and potential therapeutic applications. However, specific details regarding its synthesis, detailed mechanism, and clinical trial outcomes may vary and should be referenced from current scientific literature for the most accurate and up-to-date information.

GSK2239633: potent CCR4 antagonist, pIC50=7.9, promising for asthma due to T-helper 2 recruitment role.

CAS 2181665-31-4

GSK-2239633 (GSK2239633)

GSK2239633

Ref: TM-T69830